A competition aimed at tackling unequal access to healthcare in the NHS has been won by C2-Ai, a company that has developed an artificial intelligence-based risk assessmen
GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial.<